For digital therapeutic (DTx) startups, the question is no longer whether real-world evidence matters, but how to design a pragmatic study that generates payer-ready evidence without the time, cost, or rigidity of a classic RCT. In 2026, pragmatic study design has moved from an academic niche to a commercial necessity, especially as payers demand proof of meaningful engagement, measurable health-system impact, and safety in heterogeneous patient populations. The goal is not to abandon rigor, but to make rigor realistic by embedding study methods into the product, the care pathway, and the data infrastructure your DTx already uses.
Why Classic RCTs Don’t Scale for DTx (and What Payers Actually Want)
Classic RCTs are poor tools for evaluating software that updates weekly, adapts to user behavior, and lives outside clinic walls. A blinded placebo is nearly impossible when the intervention is an app with an interface, and by the time the trial reports, the product may have changed. Meanwhile, payers are increasingly comfortable with real-world evidence—when it addresses their coverage questions directly. They want to see whether your DTx improves adherence to existing treatments, reduces avoidable utilization, works across demographics, and performs under real-world noise.
Pragmatic studies matter because they trade artificial control for external validity. They measure outcomes as they occur, in the messy contexts where your product will actually be used. A well-designed pragmatic protocol can still include randomization, blinding of analysts, and pre-specified endpoints, but it also leverages existing clinical data, patient-reported input, and product telemetry to lower cost.
Step 1: Frame the “Coverage Question” Before You Write a Protocol
Start by identifying the single coverage decision your evidence is meant to influence. For a payer, that may be “does this DTx reduce total cost of care for patients with type 2 diabetes?” or “will this digital CBT tool lower anxiety-related medication use by 20% within six months?” Write your objective as a simple policy question, and use it to drive every design choice.
Your coverage question should also determine the comparator. Payers rarely want to see a waitlist or sham control; they want a treatment-as-usual comparison. That may mean comparing your DTx plus standard care against standard care alone, with a propensity-matched cohort from claims data or an external registry.
Step 2: Choose a Hybrid Design That Fits Your Product’s Feedback Loop
Once your coverage question is clear, pick a study architecture that aligns with your product’s actual update cycle. There are three pragmatic designs that work well for DTx startups in 2026:
- Staggered rollout (stepped wedge): If your product is deployed across multiple clinics over time, you can randomize the order in which clinics receive access. This gives you a waitlist control without holding your product back too long.
- Cluster-randomized pragmatic trial: Randomize clinics or care teams, not patients, to reduce contamination across the user base. This works best when your DTx is integrated into a workflow.
- Decentralized observational cohort with product telemetry: Enroll users directly from the app, use electronic health record (EHR) integrations for outcome measurements, and build a synthetic control arm from historical claims or existing real-world data.
You can also combine these designs. Many startups begin with a low-cost observational feasibility phase, then expand into a staged pragmatic trial once payer conversations reveal which comparator matters most.
Step 3: Define Real-World Endpoints That Map to Payer Priorities
Endpoint selection is where many DTx studies go off track. Choose outcomes that are clinically meaningful to payers, not just convenient app metrics. Daily active use is not an outcome; it’s a product metric. Payers want to see changes in blood pressure, HbA1c, PHQ-9 scores, hospital admissions, drug utilization, or productivity losses. If your app captures a validated digital endpoint, such as a digital walking test or passive symptom score, include it as a secondary measure.
Use a hierarchy of endpoints: primary clinical or utilization outcome, secondary patient-reported outcomes, and exploratory engagement/quality-of-life signals. Every endpoint should be defined in advance with a clear time window. Make sure your statistical analysis plan includes how you will handle missing data from dropouts, because real-world studies always have missingness—and payers will ask about it.
Step 4: Turn Your Product Into a Data Collection Instrument
During a pragmatic DTx study, the app itself is your most important research tool. Build structured data capture directly into the user journey instead of sending separate surveys. Log exposure time, skill completion, and mood-check responses in a standardized format that matches the endpoints you plan to analyze. Add permission-based integrations with wearable devices, pharmacy claims, or EHR portals so that outcome data flows in without requiring patients to leave the app.
Your product team will need to version-lock the relevant study features, but not the entire product. You can keep releasing non-study improvements while preventing updates to the scoring algorithms or study-facing modules. This is a key difference between classic trials and pragmatic DTx evidence generation: study validity is maintained by locking the data definitions, not the whole product.
Step 5: Build a Fit-for-Purpose Statistical Analysis Plan (SAP)
A pragmatic study still requires a pre-specified SAP. Write it before enrollment begins. But design it to handle real-world complexity without becoming so complex that it collapses under its own assumptions. Use the estimand framework promoted by regulators and payers: define the target population, the treatment condition, the endpoint, the intercurrent events like “patient deleted app,” and the population-level summary measure.
For DTx startups, the most practical approach is often a difference-in-differences analysis using repeated measures from the intervention and comparator arms. That allows you to control for baseline differences without needing perfect randomization. Prefer Bayesian or mixed-effects models when you expect a high degree of clustering by clinic or cohort. And never report a single p-value without also reporting effect size, confidence intervals, and responder analysis.
Step 6: Use Interoperability and Synthetic Controls to Boost Credibility
In 2026, payers are less impressed by a single-center pilot than by evidence that can be integrated with claims and EHR data. Use HL7® FHIR® standards to pull structured clinical data directly into your study database. This also makes your study easier to audit and interpret, because you are using the same data formats as healthcare systems.
Consider constructing a synthetic control arm from public claims datasets, previous trial data, or de-identified clinical registries. Synthetic controls can dramatically reduce the number of patients you need to enroll in the treatment arm. They are especially powerful when your coverage question involves a chronic condition with well-documented baseline trajectories, such as hypertension, diabetes, or depression.
Step 7: Run the Study Like an Engineering Sprint, Not an Academic Trial
Classic trials rely on manual case report forms, site visits, and monitors. A pragmatic DTx study should be automated, instrumented, and continuously monitored. Set up dashboards for enrollment, data completeness, and protocol deviations. Define go/no-go criteria at interim checkpoints so you can pause early if the effect is unexpectedly harmful, or expand faster if the signal is strong. This operational agility is your real advantage over a large pharma-sponsored RCT.
Make sure your team has a clear data governance plan. Real-world studies touch sensitive health information, and data minimization is both an ethical and regulatory requirement. Use privacy-preserving techniques like differential privacy or federated analysis when possible, and document your consent flow specifically for the research use of product telemetry.
Conclusion
Pragmatic study design is the most practical path for DTx startups to generate payer-ready evidence while staying fast enough to iterate on their product. By starting with a coverage question, selecting a hybrid design, embedding endpoints in the product, and using interoperability plus synthetic controls, you can produce real-world evidence that is credible, transparent, and financially feasible. The standard for success is not a perfect RCT, but a rigorously built study that reflects how patients, clinicians, and payers will actually use the therapy.
